Discover the Highest-Rated Startups of Q3 in Investment Crowdfunding

CHART OF THE WEEK 📈

By Teddy Lyons | Read

In today’s Chart of the Week, we look back at Q3 to highlight the top offerings in the equity crowdfunding landscape. First, we highlight the top-rated deals in Q3 on the Kingscrowd platform. Additionally, we look at the companies that drew in the most capital investment from retail investors.

• Alleviate, a startup revolutionizing physical therapy, led the way with a 4.94 rating

• IoT software startup AtomBeam rated a strong 4.92 rating on its fourth crowdfunding campaign.

• LiquidPiston, who is creating the next generation of hybrid engines, rated a 4.91.

• Intergen Data, a company using AI and machine learning to predict life events, rated a 4.88

• BlindTiger, an equity crowdfunding newcomer selling spirit-free cocktails, also rated a 4.88

• In terms of dollars raised, AtomBeam led the way with $4.5M raised in Q3, while AI-powered Biotech platform Syntensor came in close second place with $4.2M raised.

• Fathom, Orange Comet, and 4BiddenKnowledge all raised between $1.7 million to $2.1 million.

To learn more about Q3 in investment crowdfunding, including data and our chart on top platforms, industries, equity and debt raises, see our full article here.

INVESTMENT ROUNDTABLE

By Sam Fiske / Watch

In this episode of Investment Roundtable, Brian, Léa, and Teddy dive into key investment topics, starting with an analysis of the top five pre-revenue companies currently raising capital, particularly in the medtech space. They discuss how to evaluate early-stage ventures by examining their funding sources, burn rates, and risk factors like 510(k) clearance. The conversation then shifts to fractional offerings, featuring World Tree—a unique investment in a batch of trees with long-term returns—and other opportunities like investing in athletes or song royalties, highlighting how these offerings can provide diversification and stability for investors.

PITCH REVIEW 💸

By Teddy Lyons \ Deal Report

Brief: 72% of Americans between the ages of 35-65 suffer from hormone imbalance, yet just 12% find treatment due to high cost and lack of access. Hormonal imbalances can lead to various health concerns, such as fatigue, mood swings, and weight gain. These issues are common as individuals age and can significantly impact their quality of life. Traditional healthcare solutions often fail to provide personalized and accessible treatment options, leaving many individuals without effective care. Thrivelab solves this problem by offering personalized hormone replacement therapy programs supported by board-certified providers accessible via telehealth. Thrivelab accepts all major insurance for these treatments and also just recently launched a primary care service for existing patients.

Key People: Thrivelab is led by Co-Founder and CEO Joshua Host, who has held numerous executive positions at companies like Urban Village, Antiresort, and My Loan Host. As Principal at Urban Village, he developed and sold four residential and commercial real estate projects. He holds an MBA from Pepperdine. 

Dr. Nayan Patel serves as Chief Clinical Officer of Thrivelab. He has run Central Drugs Compounding Pharmacies, a pharmacy specializing in hormone therapy, for the last 25+ years. He holds a Doctor of Pharmacy (PharmD) from the University of Southern California and has served over 250,000+ patients with hormone health plans. 

Rahula Kocha is the CTO and CEO of iCelerate, an IT consulting company. He is also the Founder and CEO of West Valley Endocrinology, Diabetes, and Metabolism Center, a leading Phoenix-based Endocrinology Center. He holds an MS/BS in Computer Science and mathematics from Northern Illinois University.

Summary

Here's what we like: There is a clear need for more efficient hormonal therapy across the United States, and it seems like Thrivelab has demonstrated a clear product-market fit with 2023 revenue of $5.37M (up 193% from 2022). The company has done so at 60% gross margins and a 95% subscription retention rate. Thrivelab also has a strong LTV/CAC ratio of 7.5X (far exceeding the 3X ratio we benchmark against). The financial profile of Thrivelab is strong and reasonably priced at 3.7X 2023 revenues, and it represents an attractive entry point for investors.

Here's what we don't: While Thrivelab has demonstrated product-market fit, the company carries considerable funding risk with a monthly burn rate of $66,000 and cash-on-hand of just $32,000 (as of August 2024). While the company may have improved its runway in the last couple of months, there is no doubt that Thrivelab’s business model is extremely capital-intensive and may take a long time to reach profitability. Additionally, the competitive landscape is quite extensive, with competitors like Defy Medical, Alloy Health, Winona, Midi Health, and many others offering similar services. Although Thrivelab has begun to expand into new service lines (like primary care), the company will likely need to continue providing new offerings to compete with the telehealth landscape, which is only getting more competitive.

LAST WEEK’S POLL RESULTS

Would you invest in StorEn Technologies?

🟩🟩🟩🟩🟩🟩 👍 (14)

🟨🟨🟨🟨⬜️⬜️ 👎 (11)

25 Votes

Events

Join Kingscrowd’s Startup Showcase in LA

Sponsored by Fidelity Private Markets, this exciting Startup Showcase event on Wednesday, October 16th at 5pm at Industrious is your chance to hear pitches from five innovative founders, both local and from across the country, who are raising capital via RegCF—so anyone can invest. Whether you're investing $500 or $500,000, you’ll discover your next startup opportunity, from seasoned entrepreneurs with millions in revenue to founders just getting started. Plus, enjoy a unique networking experience with fellow investors and entrepreneurs. Don't miss out—back the future today!

STAFF PICKS 🌶️

Experfy

Experfy is an AI-driven SaaS platform that helps enterprises build custom communities of elite talent. Founded in the Harvard Innovation Lab and serving clients like Deloitte, Experfy offers a talent marketplace with access to over 550 million profiles, streamlining talent acquisition for government and enterprise clients. In 2023, the company reported $9.4 million in revenue. Experfy addresses the inefficiency of traditional hiring processes by using AI-powered tools, such as Talent Stream and Talent Recruit, to source, vet, and manage top candidates efficiently, reducing hiring times and improving workforce quality.

• Pre-Money Valuation: $49.9 million

• Minimum Investment: $397

Groundfloor

Groundfloor is a real estate lending platform that enables individual investors to participate in residential real estate projects with as little as $10. By originating and underwriting loans for single-family home developments and converting them into Limited Recourse Obligations (LROs), Groundfloor allows over 270,000 users to invest in real estate. With $300 million in assets under management, the platform addresses the limited access to real estate investments for smaller investors, offering a vetted and structured way to diversify their portfolios.

• Pre-Money Valuation: $289 million

• Minimum Investment: $100

Trevi Systems

Trevi Systems is a technology company specializing in low-energy, sustainable Forward Osmosis (FO) water purification systems. The company focuses on desalinating salt and brackish water and treating industrial and municipal wastewater for industries like mining, agriculture, and industrial clients. The technology purifies water efficiently and recovers valuable minerals, offering a sustainable solution to water scarcity and wastewater management challenges.

• Pre-Money Valuation: $120 million

• Minimum Investment: $1,000

Enjoyed this newsletter? Forward it to an investing-minded friend and have them signup here.